These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 22014118)
21. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F; Marconi S Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107 [TBL] [Abstract][Full Text] [Related]
22. Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. Arica B; Kaş HS; Moghdam A; Akalan N; Hincal AA J Control Release; 2005 Feb; 102(3):689-97. PubMed ID: 15681090 [TBL] [Abstract][Full Text] [Related]
23. Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson's disease. Pinnen F; Cacciatore I; Cornacchia C; Sozio P; Cerasa LS; Iannitelli A; Nasuti C; Cantalamessa F; Sekar D; Gabbianelli R; Falcioni ML; Di Stefano A J Med Chem; 2009 Jan; 52(2):559-63. PubMed ID: 19093882 [TBL] [Abstract][Full Text] [Related]
24. Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II: effect of degradation on targeting activity. Eniola AO; Hammer DA Biomaterials; 2005 Feb; 26(6):661-70. PubMed ID: 15282144 [TBL] [Abstract][Full Text] [Related]
25. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594 [TBL] [Abstract][Full Text] [Related]
26. Enhanced gentamicin loading and release of PLGA and PLHMGA microspheres by varying the formulation parameters. Chaisri W; Ghassemi AH; Hennink WE; Okonogi S Colloids Surf B Biointerfaces; 2011 Jun; 84(2):508-14. PubMed ID: 21353499 [TBL] [Abstract][Full Text] [Related]
28. Preparation and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid) microspheres using a double emulsion/solvent evaporation technique. Karal-Yılmaz O; Serhatlı M; Baysal K; Baysal BM J Microencapsul; 2011; 28(1):46-54. PubMed ID: 21171816 [TBL] [Abstract][Full Text] [Related]
29. Enhanced targeting efficiency of PLGA microspheres loaded with Lornoxicam for intra-articular administration. Zhang Z; Bi X; Li H; Huang G Drug Deliv; 2011; 18(7):536-44. PubMed ID: 21812757 [TBL] [Abstract][Full Text] [Related]
30. Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies. Liu FI; Kuo JH; Sung KC; Hu OY Int J Pharm; 2003 May; 257(1-2):23-31. PubMed ID: 12711158 [TBL] [Abstract][Full Text] [Related]
31. Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. Fernández-Carballido A; Herrero-Vanrell R; Molina-Martínez IT; Pastoriza P Int J Pharm; 2004 Jul; 279(1-2):33-41. PubMed ID: 15234792 [TBL] [Abstract][Full Text] [Related]
32. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635 [TBL] [Abstract][Full Text] [Related]
33. Biodegradation and biocompatibility of contraceptive-steroid-loaded poly (DL-lactide-co-glycolide) injectable microspheres: in vitro and in vivo study. Dhanaraju MD; Rajkannan R; Selvaraj D; Jayakumar R; Vamsadhara C Contraception; 2006 Aug; 74(2):148-56. PubMed ID: 16860053 [TBL] [Abstract][Full Text] [Related]
34. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079 [TBL] [Abstract][Full Text] [Related]
35. Development and characterization of interleukin-18-loaded biodegradable microspheres. Lagarce F; Garcion E; Faisant N; Thomas O; Kanaujia P; Menei P; Benoit JP Int J Pharm; 2006 May; 314(2):179-88. PubMed ID: 16515850 [TBL] [Abstract][Full Text] [Related]
36. Effect of mean diameter and polydispersity of PLG microspheres on drug release: experiment and theory. Berchane NS; Carson KH; Rice-Ficht AC; Andrews MJ Int J Pharm; 2007 Jun; 337(1-2):118-26. PubMed ID: 17289316 [TBL] [Abstract][Full Text] [Related]
37. Effect of PLGA hydrophilia on the drug release and the hypoglucemic activity of different insulin-loaded PLGA microspheres. Presmanes C; de Miguel L; Espada R; Alvarez C; Morales E; Torrado JJ J Microencapsul; 2011; 28(8):791-8. PubMed ID: 21967461 [TBL] [Abstract][Full Text] [Related]
38. New L-dopa codrugs as potential antiparkinson agents. Sozio P; Iannitelli A; Cerasa LS; Cacciatore I; Cornacchia C; Giorgioni G; Ricciutelli M; Nasuti C; Cantalamessa F; Di Stefano A Arch Pharm (Weinheim); 2008 Jul; 341(7):412-7. PubMed ID: 18581391 [TBL] [Abstract][Full Text] [Related]
39. Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant. Pinto E; Zhang B; Song S; Bodor N; Buchwald P; Hochhaus G Pharmazie; 2010 Jun; 65(6):429-35. PubMed ID: 20614691 [TBL] [Abstract][Full Text] [Related]
40. Porous hydroxyapatite scaffold with three-dimensional localized drug delivery system using biodegradable microspheres. Son JS; Appleford M; Ong JL; Wenke JC; Kim JM; Choi SH; Oh DS J Control Release; 2011 Jul; 153(2):133-40. PubMed ID: 21420453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]